Our experimental data using GW7647 also lead to the same conclusion and to the suggestion that the activation of the PPAR-α/PGC-1α/NRF2/TFAM pathway and mtDNA biosynthesis at an early stage of AD could be the most relevant way to delay pathology [20]. This evidence concerns the gene PPARGC1A and Alzheimer disease.